Figure 2.

Phenotypic analysis of a patient who received stereotactic body radiation therapy with concurrent pembrolizumab. A, Gating strategies for assessing the expression of PD-1 on CD4⁺ and CD8⁺ T cells. Gates for PD-1⁺ expression were based on fluorescence minus one (FMO) for PD-1 staining. Baseline and 3 months posttreatment (3MO) samples are shown. B, Graphs showing PD-1⁺ cells, Tregs, and cell counts of CD4⁺ and CD8⁺ T cells from one patient. C, PD-1⁺ CD4 and CD8 T cells in all patients through treatment. PRE, pretreatment/baseline; EOT, end of treatment.